2013,Vol 27, No 4
Bar chart showing change in heel
LEP:TP ratio over 28-day period in
(From left to right) a. Normal uninjured skin (right heel); b. injured skin (right heel), day 0; c. injured skin (right heel) treated with
KerraPro Heel, day 28.
(From left to right) a. Normal uninjured skin (left heel); b. injured skin (left heel) day 0; c. injured skin (left heel) treated with KerraPro
Heel, day 28.
ulcer development, and also
confirmed clinical assessment
based on erythema intensity,
palpable oedema and sensitivity/
pain, as well as the subjects’
position and heel condition
(e.g. atrophy of heel pad, skin
presentation, vascular or venous
Furthermore, using one pad
per patient for the duration of
the study demonstrated cost-
effectiveness, compared with the
usual interventions, where more
frequent replacements are needed.
In this evaluation, it was found that
the other pads used tended to last
between five and 14 days before
starting to split, thus reducing
their effectiveness and potentially
causing high pressure areas.
Similar outcomes in the remaining
10 patients will strengthen the
significance of these findings.
However, the findings from this
interim report show that KerraPro
is a cost and clinically-effective
pressure-reducing product that
can be used in a care home setting
to reduce the development of
preventable pressure ulceration.
Bo M, Massaia M, Raspo S, et al (2003)
Predictive factors of in-hospital
mortality in older patients admitted
to a medical intensive care unit.
Clark M, Bours G, Defloor T (2004)
The prevalence of pressure ulcers in
Recent Advances in Tissue
. Quay Books, Salisbury
Costa B (2013) Pressure ulcers:
assessment and prevention in the
Nurs Residential Care
Dealey C, Posnett J, Walker A (2012) The
cost of pressure ulcers in the United
J Wound Care
Department of Health (2010a) Equity
and Excellence: Liberating the NHS.
DH, London. Available at:
Department of Health (2010b)
Transparency in outcomes — a
framework for the NHS. DH, London.